69 Afatinib versus gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC) harbouring activating EGFR mutations: results of the global, randomised, open-label, phase IIb trial LUX-Lung 7. (January 2016) - O'Byrne, K.J.; Park, K.; Tan, E.; Zhang, L.; Hirsh, V.; Boyer, M.; Yang, J.C.; Mok, T.; Kim, M.; Massey, D.; Zazulina, V.; Paz-Ares, L.